Covid

TREATMENT

Andhra govt to bear Rs 1.5 cr treatment cost for COVID positive doctor



ANI |
Updated:
Jun 05, 2021 22:29 IST

Amaravati (Andhra Pradesh) [India], June 5 (ANI): The Andhra Pradesh government will bear the cost of treatment amounting to Rs 1.5 crore of a doctor named N Bhaskar Rao who tested positive for COVID-19.
Andhra Pradesh Chief Minister YS Jagan Mohan Reddy has announced that the government will bear the cost of treatment amounting to Rs 1.5 crore for Government Doctor N. Bhaskar Rao, who has been battling for his life at Care hospitals, Gachibowli, informed an official release on Saturday.
Dr. N. Bhaskar Rao, 38, working as a medical officer in Public Healthcare Centre (PHC), Karamchedu of Prakasam district has got tested positive for COVID and his wife Dr. Bhagya Laxmi, 38, working as Assistant professor, radio diagnosis in Guntur Medical College also tested positive for COVID. Both of them were admitted to GGH, Guntur on April 30, and both took

Read More Read More
TREATMENT

COVID treatment has improved, but many wish for an easy pill | National News

If Priscila Medina had gotten COVID-19 a year ago, she would have had no treatments proven safe and effective to try. But when the 30-year-old nurse arrived at a Long Island hospital last month, so short of breath she could barely talk, doctors knew just what to do.

They quickly arranged for her to get a novel drug that supplies virus-blocking antibodies, and “by the next day I was able to get up and move around,” she said. After two days, “I really started turning the corner. I was showering, eating, playing with my son.”

Treatments like these can help newly diagnosed patients avoid hospitalization, but they are grossly underused because they require an IV. Other medicines for sicker patients can speed recovery, but only a few improve survival.

While vaccines are helping to curb the pandemic, easier and better treatments are needed, especially as virus variants spread.

“We’re seeing

Read More Read More
TREATMENT

Demand for key option for COVID treatment increases | Somerset

A key treatment option for those who get mild to moderate COVID-19 symptoms is growing in use, health care professionals said during a media conference Friday.

The treatment is monoclonal antibodies infusion.

Basically, the therapy reduces the likelihood of a patient experiencing severe effects of COVID-19 that can place them in a hospital, perhaps on a ventilator or even death from complications of the virus, health care officials said.



Boswell woman recalls COVID treatment

Karen Ryan, her sister and her mother are close. They enjoy spending all their time together.

“The demand for monoclonal antibodies therapy has more than quadrupled in the last three weeks,” said Tami Minnier, UPMC chief quality officer. “We now have 45 sites able to perform the treatment.”






Tami Minnier

Tami Minnier, chief quality officer at UPMC, discusses the importance of COVID-19 vaccines during a media conference Friday.


The three larger health care systems in and near Somerset County — UPMC

Read More Read More
HEALTH

New Covid strain: Genetics experts worry vaccines might not work quite as well against UK variant

“This is the first variant I’ve seen during the whole pandemic where I took a step back and said: ‘Whoa,’ ” he remembers.

Health officials have downplayed the possibility that the coronavirus vaccines won’t work against the UK strain, but Worobey and other scientists thinks it’s a possibility — and it’s just a possibility — that this new variant might, to a small extent, outsmart the vaccines.

“This is the first variant I’ve seen where I think there is this burning question,” said Worobey, head of the department of ecology and evolutionary biology at the University of Arizona.

Trevor Bedford, an associate professor in the vaccine and infectious disease division of the Fred Hutchinson Cancer Research Center, is also keeping a close eye on the UK variant.

Large clinical trials have shown that the vaccines by Pfizer/BioNTech and Moderna are about 95% effective against the novel coronavirus. Those trials, however,

Read More Read More